Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM)
Objective Glioblastoma multiforme (GBM) is a nearly uniformly fatal brain tumor with a median recurrence rate of 7 months and survival of 14 months after multimodality treatment. We sought to evaluate outcomes based on the presence or absence of symptoms at the time of recurrence. Methods We reviewe...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Amini, Arya [verfasserIn] Altoos, Basel [verfasserIn] Karam, Sana D. [verfasserIn] Waxweiler, Timothy V. [verfasserIn] Rusthoven, Chad G. [verfasserIn] Gaspar, Laurie E. [verfasserIn] Honce, Justin M. [verfasserIn] Damek, Denise M. [verfasserIn] Ney, Douglas E. [verfasserIn] Ormond, D. Ryan [verfasserIn] Lillehei, Kevin O. [verfasserIn] Chen, Changhu [verfasserIn] Kavanagh, Brian D. [verfasserIn] Liu, Arthur K. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Journal of radiation oncology - Berlin : Springer, 2012, 5(2015), 1 vom: 12. Nov., Seite 33-39 |
|---|---|
| Übergeordnetes Werk: |
volume:5 ; year:2015 ; number:1 ; day:12 ; month:11 ; pages:33-39 |
| Links: |
|---|
| DOI / URN: |
10.1007/s13566-015-0231-6 |
|---|
| Katalog-ID: |
SPR03181168X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR03181168X | ||
| 003 | DE-627 | ||
| 005 | 20230519141839.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13566-015-0231-6 |2 doi | |
| 035 | |a (DE-627)SPR03181168X | ||
| 035 | |a (SPR)s13566-015-0231-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Amini, Arya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM) |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objective Glioblastoma multiforme (GBM) is a nearly uniformly fatal brain tumor with a median recurrence rate of 7 months and survival of 14 months after multimodality treatment. We sought to evaluate outcomes based on the presence or absence of symptoms at the time of recurrence. Methods We reviewed 60 patients with GBM treated from 2007 to 2014. All patients had documented radiographic evidence of recurrence. Symptomatic recurrence was defined as development of new or recurring symptoms prior to evidence of radiographic recurrence; those in this group had follow-up imaging confirming recurrence. Asymptomatic recurrence was defined as unequivocal evidence of recurrence on MRI. Results Median age for the symptomatic and asymptomatic groups was 58 and 57 years, respectively. Recursive partitioning analysis classes and other clinical factors were similar between both groups. The median time to recurrence was 9.5 months (range 3–49 months). Forty relapses (66.7 %) were symptomatic; 20 (33.3 %) were asymptomatic. Median overall survival (OS) for the symptomatic and asymptomatic cohorts was 17 and 23 months, respectively, a relative difference of 6 months (p = 0.08). Post-relapse survival was 3 months in patients who recurred symptomatically and 10 months for those who recurred by imaging (p = 0.06). Among the asymptomatic recurrence cohort, those who later went on to develop symptoms also had a median survival from symptom onset of 3 months. Conclusions In summary, OS is worse in GBM patients who present with symptoms at time of recurrence. This difference in survival is relatively large and should be validated in larger patient cohorts. | ||
| 650 | 4 | |a Glioblastoma multiforme (GBM) |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Symptomatic recurrence |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Asymptomatic recurrence |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Survival outcomes |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Altoos, Basel |e verfasserin |4 aut | |
| 700 | 1 | |a Karam, Sana D. |e verfasserin |4 aut | |
| 700 | 1 | |a Waxweiler, Timothy V. |e verfasserin |4 aut | |
| 700 | 1 | |a Rusthoven, Chad G. |e verfasserin |4 aut | |
| 700 | 1 | |a Gaspar, Laurie E. |e verfasserin |4 aut | |
| 700 | 1 | |a Honce, Justin M. |e verfasserin |4 aut | |
| 700 | 1 | |a Damek, Denise M. |e verfasserin |4 aut | |
| 700 | 1 | |a Ney, Douglas E. |e verfasserin |4 aut | |
| 700 | 1 | |a Ormond, D. Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Lillehei, Kevin O. |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Changhu |e verfasserin |4 aut | |
| 700 | 1 | |a Kavanagh, Brian D. |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Arthur K. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of radiation oncology |d Berlin : Springer, 2012 |g 5(2015), 1 vom: 12. Nov., Seite 33-39 |w (DE-627)718611233 |w (DE-600)2660511-9 |x 1948-7908 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2015 |g number:1 |g day:12 |g month:11 |g pages:33-39 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13566-015-0231-6 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_32 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_138 | ||
| 912 | |a GBV_ILN_150 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_187 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_250 | ||
| 912 | |a GBV_ILN_281 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_636 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2020 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2025 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a GBV_ILN_2031 | ||
| 912 | |a GBV_ILN_2034 | ||
| 912 | |a GBV_ILN_2037 | ||
| 912 | |a GBV_ILN_2038 | ||
| 912 | |a GBV_ILN_2039 | ||
| 912 | |a GBV_ILN_2044 | ||
| 912 | |a GBV_ILN_2048 | ||
| 912 | |a GBV_ILN_2049 | ||
| 912 | |a GBV_ILN_2050 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2057 | ||
| 912 | |a GBV_ILN_2059 | ||
| 912 | |a GBV_ILN_2061 | ||
| 912 | |a GBV_ILN_2064 | ||
| 912 | |a GBV_ILN_2065 | ||
| 912 | |a GBV_ILN_2068 | ||
| 912 | |a GBV_ILN_2070 | ||
| 912 | |a GBV_ILN_2086 | ||
| 912 | |a GBV_ILN_2088 | ||
| 912 | |a GBV_ILN_2093 | ||
| 912 | |a GBV_ILN_2106 | ||
| 912 | |a GBV_ILN_2107 | ||
| 912 | |a GBV_ILN_2108 | ||
| 912 | |a GBV_ILN_2110 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2112 | ||
| 912 | |a GBV_ILN_2113 | ||
| 912 | |a GBV_ILN_2116 | ||
| 912 | |a GBV_ILN_2118 | ||
| 912 | |a GBV_ILN_2119 | ||
| 912 | |a GBV_ILN_2122 | ||
| 912 | |a GBV_ILN_2129 | ||
| 912 | |a GBV_ILN_2143 | ||
| 912 | |a GBV_ILN_2144 | ||
| 912 | |a GBV_ILN_2147 | ||
| 912 | |a GBV_ILN_2148 | ||
| 912 | |a GBV_ILN_2152 | ||
| 912 | |a GBV_ILN_2153 | ||
| 912 | |a GBV_ILN_2188 | ||
| 912 | |a GBV_ILN_2232 | ||
| 912 | |a GBV_ILN_2336 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_2470 | ||
| 912 | |a GBV_ILN_2472 | ||
| 912 | |a GBV_ILN_2507 | ||
| 912 | |a GBV_ILN_2522 | ||
| 912 | |a GBV_ILN_2548 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4046 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4242 | ||
| 912 | |a GBV_ILN_4246 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4251 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4326 | ||
| 912 | |a GBV_ILN_4333 | ||
| 912 | |a GBV_ILN_4334 | ||
| 912 | |a GBV_ILN_4335 | ||
| 912 | |a GBV_ILN_4336 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4393 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2015 |e 1 |b 12 |c 11 |h 33-39 | ||
| author_variant |
a a aa b a ba s d k sd sdk t v w tv tvw c g r cg cgr l e g le leg j m h jm jmh d m d dm dmd d e n de den d r o dr dro k o l ko kol c c cc b d k bd bdk a k l ak akl |
|---|---|
| matchkey_str |
article:19487908:2015----::ucmsfypoaicmaetaypoaircrecsnainsih |
| hierarchy_sort_str |
2015 |
| publishDate |
2015 |
| allfields |
10.1007/s13566-015-0231-6 doi (DE-627)SPR03181168X (SPR)s13566-015-0231-6-e DE-627 ger DE-627 rakwb eng 610 ASE Amini, Arya verfasserin aut Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM) 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective Glioblastoma multiforme (GBM) is a nearly uniformly fatal brain tumor with a median recurrence rate of 7 months and survival of 14 months after multimodality treatment. We sought to evaluate outcomes based on the presence or absence of symptoms at the time of recurrence. Methods We reviewed 60 patients with GBM treated from 2007 to 2014. All patients had documented radiographic evidence of recurrence. Symptomatic recurrence was defined as development of new or recurring symptoms prior to evidence of radiographic recurrence; those in this group had follow-up imaging confirming recurrence. Asymptomatic recurrence was defined as unequivocal evidence of recurrence on MRI. Results Median age for the symptomatic and asymptomatic groups was 58 and 57 years, respectively. Recursive partitioning analysis classes and other clinical factors were similar between both groups. The median time to recurrence was 9.5 months (range 3–49 months). Forty relapses (66.7 %) were symptomatic; 20 (33.3 %) were asymptomatic. Median overall survival (OS) for the symptomatic and asymptomatic cohorts was 17 and 23 months, respectively, a relative difference of 6 months (p = 0.08). Post-relapse survival was 3 months in patients who recurred symptomatically and 10 months for those who recurred by imaging (p = 0.06). Among the asymptomatic recurrence cohort, those who later went on to develop symptoms also had a median survival from symptom onset of 3 months. Conclusions In summary, OS is worse in GBM patients who present with symptoms at time of recurrence. This difference in survival is relatively large and should be validated in larger patient cohorts. Glioblastoma multiforme (GBM) (dpeaa)DE-He213 Symptomatic recurrence (dpeaa)DE-He213 Asymptomatic recurrence (dpeaa)DE-He213 Survival outcomes (dpeaa)DE-He213 Altoos, Basel verfasserin aut Karam, Sana D. verfasserin aut Waxweiler, Timothy V. verfasserin aut Rusthoven, Chad G. verfasserin aut Gaspar, Laurie E. verfasserin aut Honce, Justin M. verfasserin aut Damek, Denise M. verfasserin aut Ney, Douglas E. verfasserin aut Ormond, D. Ryan verfasserin aut Lillehei, Kevin O. verfasserin aut Chen, Changhu verfasserin aut Kavanagh, Brian D. verfasserin aut Liu, Arthur K. verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 5(2015), 1 vom: 12. Nov., Seite 33-39 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:5 year:2015 number:1 day:12 month:11 pages:33-39 https://dx.doi.org/10.1007/s13566-015-0231-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 5 2015 1 12 11 33-39 |
| spelling |
10.1007/s13566-015-0231-6 doi (DE-627)SPR03181168X (SPR)s13566-015-0231-6-e DE-627 ger DE-627 rakwb eng 610 ASE Amini, Arya verfasserin aut Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM) 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective Glioblastoma multiforme (GBM) is a nearly uniformly fatal brain tumor with a median recurrence rate of 7 months and survival of 14 months after multimodality treatment. We sought to evaluate outcomes based on the presence or absence of symptoms at the time of recurrence. Methods We reviewed 60 patients with GBM treated from 2007 to 2014. All patients had documented radiographic evidence of recurrence. Symptomatic recurrence was defined as development of new or recurring symptoms prior to evidence of radiographic recurrence; those in this group had follow-up imaging confirming recurrence. Asymptomatic recurrence was defined as unequivocal evidence of recurrence on MRI. Results Median age for the symptomatic and asymptomatic groups was 58 and 57 years, respectively. Recursive partitioning analysis classes and other clinical factors were similar between both groups. The median time to recurrence was 9.5 months (range 3–49 months). Forty relapses (66.7 %) were symptomatic; 20 (33.3 %) were asymptomatic. Median overall survival (OS) for the symptomatic and asymptomatic cohorts was 17 and 23 months, respectively, a relative difference of 6 months (p = 0.08). Post-relapse survival was 3 months in patients who recurred symptomatically and 10 months for those who recurred by imaging (p = 0.06). Among the asymptomatic recurrence cohort, those who later went on to develop symptoms also had a median survival from symptom onset of 3 months. Conclusions In summary, OS is worse in GBM patients who present with symptoms at time of recurrence. This difference in survival is relatively large and should be validated in larger patient cohorts. Glioblastoma multiforme (GBM) (dpeaa)DE-He213 Symptomatic recurrence (dpeaa)DE-He213 Asymptomatic recurrence (dpeaa)DE-He213 Survival outcomes (dpeaa)DE-He213 Altoos, Basel verfasserin aut Karam, Sana D. verfasserin aut Waxweiler, Timothy V. verfasserin aut Rusthoven, Chad G. verfasserin aut Gaspar, Laurie E. verfasserin aut Honce, Justin M. verfasserin aut Damek, Denise M. verfasserin aut Ney, Douglas E. verfasserin aut Ormond, D. Ryan verfasserin aut Lillehei, Kevin O. verfasserin aut Chen, Changhu verfasserin aut Kavanagh, Brian D. verfasserin aut Liu, Arthur K. verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 5(2015), 1 vom: 12. Nov., Seite 33-39 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:5 year:2015 number:1 day:12 month:11 pages:33-39 https://dx.doi.org/10.1007/s13566-015-0231-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 5 2015 1 12 11 33-39 |
| allfields_unstemmed |
10.1007/s13566-015-0231-6 doi (DE-627)SPR03181168X (SPR)s13566-015-0231-6-e DE-627 ger DE-627 rakwb eng 610 ASE Amini, Arya verfasserin aut Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM) 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective Glioblastoma multiforme (GBM) is a nearly uniformly fatal brain tumor with a median recurrence rate of 7 months and survival of 14 months after multimodality treatment. We sought to evaluate outcomes based on the presence or absence of symptoms at the time of recurrence. Methods We reviewed 60 patients with GBM treated from 2007 to 2014. All patients had documented radiographic evidence of recurrence. Symptomatic recurrence was defined as development of new or recurring symptoms prior to evidence of radiographic recurrence; those in this group had follow-up imaging confirming recurrence. Asymptomatic recurrence was defined as unequivocal evidence of recurrence on MRI. Results Median age for the symptomatic and asymptomatic groups was 58 and 57 years, respectively. Recursive partitioning analysis classes and other clinical factors were similar between both groups. The median time to recurrence was 9.5 months (range 3–49 months). Forty relapses (66.7 %) were symptomatic; 20 (33.3 %) were asymptomatic. Median overall survival (OS) for the symptomatic and asymptomatic cohorts was 17 and 23 months, respectively, a relative difference of 6 months (p = 0.08). Post-relapse survival was 3 months in patients who recurred symptomatically and 10 months for those who recurred by imaging (p = 0.06). Among the asymptomatic recurrence cohort, those who later went on to develop symptoms also had a median survival from symptom onset of 3 months. Conclusions In summary, OS is worse in GBM patients who present with symptoms at time of recurrence. This difference in survival is relatively large and should be validated in larger patient cohorts. Glioblastoma multiforme (GBM) (dpeaa)DE-He213 Symptomatic recurrence (dpeaa)DE-He213 Asymptomatic recurrence (dpeaa)DE-He213 Survival outcomes (dpeaa)DE-He213 Altoos, Basel verfasserin aut Karam, Sana D. verfasserin aut Waxweiler, Timothy V. verfasserin aut Rusthoven, Chad G. verfasserin aut Gaspar, Laurie E. verfasserin aut Honce, Justin M. verfasserin aut Damek, Denise M. verfasserin aut Ney, Douglas E. verfasserin aut Ormond, D. Ryan verfasserin aut Lillehei, Kevin O. verfasserin aut Chen, Changhu verfasserin aut Kavanagh, Brian D. verfasserin aut Liu, Arthur K. verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 5(2015), 1 vom: 12. Nov., Seite 33-39 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:5 year:2015 number:1 day:12 month:11 pages:33-39 https://dx.doi.org/10.1007/s13566-015-0231-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 5 2015 1 12 11 33-39 |
| allfieldsGer |
10.1007/s13566-015-0231-6 doi (DE-627)SPR03181168X (SPR)s13566-015-0231-6-e DE-627 ger DE-627 rakwb eng 610 ASE Amini, Arya verfasserin aut Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM) 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective Glioblastoma multiforme (GBM) is a nearly uniformly fatal brain tumor with a median recurrence rate of 7 months and survival of 14 months after multimodality treatment. We sought to evaluate outcomes based on the presence or absence of symptoms at the time of recurrence. Methods We reviewed 60 patients with GBM treated from 2007 to 2014. All patients had documented radiographic evidence of recurrence. Symptomatic recurrence was defined as development of new or recurring symptoms prior to evidence of radiographic recurrence; those in this group had follow-up imaging confirming recurrence. Asymptomatic recurrence was defined as unequivocal evidence of recurrence on MRI. Results Median age for the symptomatic and asymptomatic groups was 58 and 57 years, respectively. Recursive partitioning analysis classes and other clinical factors were similar between both groups. The median time to recurrence was 9.5 months (range 3–49 months). Forty relapses (66.7 %) were symptomatic; 20 (33.3 %) were asymptomatic. Median overall survival (OS) for the symptomatic and asymptomatic cohorts was 17 and 23 months, respectively, a relative difference of 6 months (p = 0.08). Post-relapse survival was 3 months in patients who recurred symptomatically and 10 months for those who recurred by imaging (p = 0.06). Among the asymptomatic recurrence cohort, those who later went on to develop symptoms also had a median survival from symptom onset of 3 months. Conclusions In summary, OS is worse in GBM patients who present with symptoms at time of recurrence. This difference in survival is relatively large and should be validated in larger patient cohorts. Glioblastoma multiforme (GBM) (dpeaa)DE-He213 Symptomatic recurrence (dpeaa)DE-He213 Asymptomatic recurrence (dpeaa)DE-He213 Survival outcomes (dpeaa)DE-He213 Altoos, Basel verfasserin aut Karam, Sana D. verfasserin aut Waxweiler, Timothy V. verfasserin aut Rusthoven, Chad G. verfasserin aut Gaspar, Laurie E. verfasserin aut Honce, Justin M. verfasserin aut Damek, Denise M. verfasserin aut Ney, Douglas E. verfasserin aut Ormond, D. Ryan verfasserin aut Lillehei, Kevin O. verfasserin aut Chen, Changhu verfasserin aut Kavanagh, Brian D. verfasserin aut Liu, Arthur K. verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 5(2015), 1 vom: 12. Nov., Seite 33-39 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:5 year:2015 number:1 day:12 month:11 pages:33-39 https://dx.doi.org/10.1007/s13566-015-0231-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 5 2015 1 12 11 33-39 |
| allfieldsSound |
10.1007/s13566-015-0231-6 doi (DE-627)SPR03181168X (SPR)s13566-015-0231-6-e DE-627 ger DE-627 rakwb eng 610 ASE Amini, Arya verfasserin aut Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM) 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Objective Glioblastoma multiforme (GBM) is a nearly uniformly fatal brain tumor with a median recurrence rate of 7 months and survival of 14 months after multimodality treatment. We sought to evaluate outcomes based on the presence or absence of symptoms at the time of recurrence. Methods We reviewed 60 patients with GBM treated from 2007 to 2014. All patients had documented radiographic evidence of recurrence. Symptomatic recurrence was defined as development of new or recurring symptoms prior to evidence of radiographic recurrence; those in this group had follow-up imaging confirming recurrence. Asymptomatic recurrence was defined as unequivocal evidence of recurrence on MRI. Results Median age for the symptomatic and asymptomatic groups was 58 and 57 years, respectively. Recursive partitioning analysis classes and other clinical factors were similar between both groups. The median time to recurrence was 9.5 months (range 3–49 months). Forty relapses (66.7 %) were symptomatic; 20 (33.3 %) were asymptomatic. Median overall survival (OS) for the symptomatic and asymptomatic cohorts was 17 and 23 months, respectively, a relative difference of 6 months (p = 0.08). Post-relapse survival was 3 months in patients who recurred symptomatically and 10 months for those who recurred by imaging (p = 0.06). Among the asymptomatic recurrence cohort, those who later went on to develop symptoms also had a median survival from symptom onset of 3 months. Conclusions In summary, OS is worse in GBM patients who present with symptoms at time of recurrence. This difference in survival is relatively large and should be validated in larger patient cohorts. Glioblastoma multiforme (GBM) (dpeaa)DE-He213 Symptomatic recurrence (dpeaa)DE-He213 Asymptomatic recurrence (dpeaa)DE-He213 Survival outcomes (dpeaa)DE-He213 Altoos, Basel verfasserin aut Karam, Sana D. verfasserin aut Waxweiler, Timothy V. verfasserin aut Rusthoven, Chad G. verfasserin aut Gaspar, Laurie E. verfasserin aut Honce, Justin M. verfasserin aut Damek, Denise M. verfasserin aut Ney, Douglas E. verfasserin aut Ormond, D. Ryan verfasserin aut Lillehei, Kevin O. verfasserin aut Chen, Changhu verfasserin aut Kavanagh, Brian D. verfasserin aut Liu, Arthur K. verfasserin aut Enthalten in Journal of radiation oncology Berlin : Springer, 2012 5(2015), 1 vom: 12. Nov., Seite 33-39 (DE-627)718611233 (DE-600)2660511-9 1948-7908 nnns volume:5 year:2015 number:1 day:12 month:11 pages:33-39 https://dx.doi.org/10.1007/s13566-015-0231-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 5 2015 1 12 11 33-39 |
| language |
English |
| source |
Enthalten in Journal of radiation oncology 5(2015), 1 vom: 12. Nov., Seite 33-39 volume:5 year:2015 number:1 day:12 month:11 pages:33-39 |
| sourceStr |
Enthalten in Journal of radiation oncology 5(2015), 1 vom: 12. Nov., Seite 33-39 volume:5 year:2015 number:1 day:12 month:11 pages:33-39 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Glioblastoma multiforme (GBM) Symptomatic recurrence Asymptomatic recurrence Survival outcomes |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Journal of radiation oncology |
| authorswithroles_txt_mv |
Amini, Arya @@aut@@ Altoos, Basel @@aut@@ Karam, Sana D. @@aut@@ Waxweiler, Timothy V. @@aut@@ Rusthoven, Chad G. @@aut@@ Gaspar, Laurie E. @@aut@@ Honce, Justin M. @@aut@@ Damek, Denise M. @@aut@@ Ney, Douglas E. @@aut@@ Ormond, D. Ryan @@aut@@ Lillehei, Kevin O. @@aut@@ Chen, Changhu @@aut@@ Kavanagh, Brian D. @@aut@@ Liu, Arthur K. @@aut@@ |
| publishDateDaySort_date |
2015-11-12T00:00:00Z |
| hierarchy_top_id |
718611233 |
| dewey-sort |
3610 |
| id |
SPR03181168X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR03181168X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519141839.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13566-015-0231-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR03181168X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13566-015-0231-6-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Amini, Arya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objective Glioblastoma multiforme (GBM) is a nearly uniformly fatal brain tumor with a median recurrence rate of 7 months and survival of 14 months after multimodality treatment. We sought to evaluate outcomes based on the presence or absence of symptoms at the time of recurrence. Methods We reviewed 60 patients with GBM treated from 2007 to 2014. All patients had documented radiographic evidence of recurrence. Symptomatic recurrence was defined as development of new or recurring symptoms prior to evidence of radiographic recurrence; those in this group had follow-up imaging confirming recurrence. Asymptomatic recurrence was defined as unequivocal evidence of recurrence on MRI. Results Median age for the symptomatic and asymptomatic groups was 58 and 57 years, respectively. Recursive partitioning analysis classes and other clinical factors were similar between both groups. The median time to recurrence was 9.5 months (range 3–49 months). Forty relapses (66.7 %) were symptomatic; 20 (33.3 %) were asymptomatic. Median overall survival (OS) for the symptomatic and asymptomatic cohorts was 17 and 23 months, respectively, a relative difference of 6 months (p = 0.08). Post-relapse survival was 3 months in patients who recurred symptomatically and 10 months for those who recurred by imaging (p = 0.06). Among the asymptomatic recurrence cohort, those who later went on to develop symptoms also had a median survival from symptom onset of 3 months. Conclusions In summary, OS is worse in GBM patients who present with symptoms at time of recurrence. This difference in survival is relatively large and should be validated in larger patient cohorts.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Glioblastoma multiforme (GBM)</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Symptomatic recurrence</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Asymptomatic recurrence</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Survival outcomes</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Altoos, Basel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Karam, Sana D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Waxweiler, Timothy V.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rusthoven, Chad G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gaspar, Laurie E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Honce, Justin M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Damek, Denise M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ney, Douglas E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ormond, D. Ryan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lillehei, Kevin O.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Changhu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kavanagh, Brian D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Arthur K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of radiation oncology</subfield><subfield code="d">Berlin : Springer, 2012</subfield><subfield code="g">5(2015), 1 vom: 12. Nov., Seite 33-39</subfield><subfield code="w">(DE-627)718611233</subfield><subfield code="w">(DE-600)2660511-9</subfield><subfield code="x">1948-7908</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:5</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">day:12</subfield><subfield code="g">month:11</subfield><subfield code="g">pages:33-39</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13566-015-0231-6</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">5</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="b">12</subfield><subfield code="c">11</subfield><subfield code="h">33-39</subfield></datafield></record></collection>
|
| author |
Amini, Arya |
| spellingShingle |
Amini, Arya ddc 610 misc Glioblastoma multiforme (GBM) misc Symptomatic recurrence misc Asymptomatic recurrence misc Survival outcomes Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM) |
| authorStr |
Amini, Arya |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)718611233 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1948-7908 |
| topic_title |
610 ASE Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM) Glioblastoma multiforme (GBM) (dpeaa)DE-He213 Symptomatic recurrence (dpeaa)DE-He213 Asymptomatic recurrence (dpeaa)DE-He213 Survival outcomes (dpeaa)DE-He213 |
| topic |
ddc 610 misc Glioblastoma multiforme (GBM) misc Symptomatic recurrence misc Asymptomatic recurrence misc Survival outcomes |
| topic_unstemmed |
ddc 610 misc Glioblastoma multiforme (GBM) misc Symptomatic recurrence misc Asymptomatic recurrence misc Survival outcomes |
| topic_browse |
ddc 610 misc Glioblastoma multiforme (GBM) misc Symptomatic recurrence misc Asymptomatic recurrence misc Survival outcomes |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Journal of radiation oncology |
| hierarchy_parent_id |
718611233 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Journal of radiation oncology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)718611233 (DE-600)2660511-9 |
| title |
Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM) |
| ctrlnum |
(DE-627)SPR03181168X (SPR)s13566-015-0231-6-e |
| title_full |
Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM) |
| author_sort |
Amini, Arya |
| journal |
Journal of radiation oncology |
| journalStr |
Journal of radiation oncology |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
txt |
| container_start_page |
33 |
| author_browse |
Amini, Arya Altoos, Basel Karam, Sana D. Waxweiler, Timothy V. Rusthoven, Chad G. Gaspar, Laurie E. Honce, Justin M. Damek, Denise M. Ney, Douglas E. Ormond, D. Ryan Lillehei, Kevin O. Chen, Changhu Kavanagh, Brian D. Liu, Arthur K. |
| container_volume |
5 |
| class |
610 ASE |
| format_se |
Elektronische Aufsätze |
| author-letter |
Amini, Arya |
| doi_str_mv |
10.1007/s13566-015-0231-6 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (gbm) |
| title_auth |
Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM) |
| abstract |
Objective Glioblastoma multiforme (GBM) is a nearly uniformly fatal brain tumor with a median recurrence rate of 7 months and survival of 14 months after multimodality treatment. We sought to evaluate outcomes based on the presence or absence of symptoms at the time of recurrence. Methods We reviewed 60 patients with GBM treated from 2007 to 2014. All patients had documented radiographic evidence of recurrence. Symptomatic recurrence was defined as development of new or recurring symptoms prior to evidence of radiographic recurrence; those in this group had follow-up imaging confirming recurrence. Asymptomatic recurrence was defined as unequivocal evidence of recurrence on MRI. Results Median age for the symptomatic and asymptomatic groups was 58 and 57 years, respectively. Recursive partitioning analysis classes and other clinical factors were similar between both groups. The median time to recurrence was 9.5 months (range 3–49 months). Forty relapses (66.7 %) were symptomatic; 20 (33.3 %) were asymptomatic. Median overall survival (OS) for the symptomatic and asymptomatic cohorts was 17 and 23 months, respectively, a relative difference of 6 months (p = 0.08). Post-relapse survival was 3 months in patients who recurred symptomatically and 10 months for those who recurred by imaging (p = 0.06). Among the asymptomatic recurrence cohort, those who later went on to develop symptoms also had a median survival from symptom onset of 3 months. Conclusions In summary, OS is worse in GBM patients who present with symptoms at time of recurrence. This difference in survival is relatively large and should be validated in larger patient cohorts. |
| abstractGer |
Objective Glioblastoma multiforme (GBM) is a nearly uniformly fatal brain tumor with a median recurrence rate of 7 months and survival of 14 months after multimodality treatment. We sought to evaluate outcomes based on the presence or absence of symptoms at the time of recurrence. Methods We reviewed 60 patients with GBM treated from 2007 to 2014. All patients had documented radiographic evidence of recurrence. Symptomatic recurrence was defined as development of new or recurring symptoms prior to evidence of radiographic recurrence; those in this group had follow-up imaging confirming recurrence. Asymptomatic recurrence was defined as unequivocal evidence of recurrence on MRI. Results Median age for the symptomatic and asymptomatic groups was 58 and 57 years, respectively. Recursive partitioning analysis classes and other clinical factors were similar between both groups. The median time to recurrence was 9.5 months (range 3–49 months). Forty relapses (66.7 %) were symptomatic; 20 (33.3 %) were asymptomatic. Median overall survival (OS) for the symptomatic and asymptomatic cohorts was 17 and 23 months, respectively, a relative difference of 6 months (p = 0.08). Post-relapse survival was 3 months in patients who recurred symptomatically and 10 months for those who recurred by imaging (p = 0.06). Among the asymptomatic recurrence cohort, those who later went on to develop symptoms also had a median survival from symptom onset of 3 months. Conclusions In summary, OS is worse in GBM patients who present with symptoms at time of recurrence. This difference in survival is relatively large and should be validated in larger patient cohorts. |
| abstract_unstemmed |
Objective Glioblastoma multiforme (GBM) is a nearly uniformly fatal brain tumor with a median recurrence rate of 7 months and survival of 14 months after multimodality treatment. We sought to evaluate outcomes based on the presence or absence of symptoms at the time of recurrence. Methods We reviewed 60 patients with GBM treated from 2007 to 2014. All patients had documented radiographic evidence of recurrence. Symptomatic recurrence was defined as development of new or recurring symptoms prior to evidence of radiographic recurrence; those in this group had follow-up imaging confirming recurrence. Asymptomatic recurrence was defined as unequivocal evidence of recurrence on MRI. Results Median age for the symptomatic and asymptomatic groups was 58 and 57 years, respectively. Recursive partitioning analysis classes and other clinical factors were similar between both groups. The median time to recurrence was 9.5 months (range 3–49 months). Forty relapses (66.7 %) were symptomatic; 20 (33.3 %) were asymptomatic. Median overall survival (OS) for the symptomatic and asymptomatic cohorts was 17 and 23 months, respectively, a relative difference of 6 months (p = 0.08). Post-relapse survival was 3 months in patients who recurred symptomatically and 10 months for those who recurred by imaging (p = 0.06). Among the asymptomatic recurrence cohort, those who later went on to develop symptoms also had a median survival from symptom onset of 3 months. Conclusions In summary, OS is worse in GBM patients who present with symptoms at time of recurrence. This difference in survival is relatively large and should be validated in larger patient cohorts. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 |
| container_issue |
1 |
| title_short |
Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM) |
| url |
https://dx.doi.org/10.1007/s13566-015-0231-6 |
| remote_bool |
true |
| author2 |
Altoos, Basel Karam, Sana D. Waxweiler, Timothy V. Rusthoven, Chad G. Gaspar, Laurie E. Honce, Justin M. Damek, Denise M. Ney, Douglas E. Ormond, D. Ryan Lillehei, Kevin O. Chen, Changhu Kavanagh, Brian D. Liu, Arthur K. |
| author2Str |
Altoos, Basel Karam, Sana D. Waxweiler, Timothy V. Rusthoven, Chad G. Gaspar, Laurie E. Honce, Justin M. Damek, Denise M. Ney, Douglas E. Ormond, D. Ryan Lillehei, Kevin O. Chen, Changhu Kavanagh, Brian D. Liu, Arthur K. |
| ppnlink |
718611233 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s13566-015-0231-6 |
| up_date |
2024-07-04T01:20:50.641Z |
| _version_ |
1803609493361131520 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR03181168X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519141839.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13566-015-0231-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR03181168X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13566-015-0231-6-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Amini, Arya</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objective Glioblastoma multiforme (GBM) is a nearly uniformly fatal brain tumor with a median recurrence rate of 7 months and survival of 14 months after multimodality treatment. We sought to evaluate outcomes based on the presence or absence of symptoms at the time of recurrence. Methods We reviewed 60 patients with GBM treated from 2007 to 2014. All patients had documented radiographic evidence of recurrence. Symptomatic recurrence was defined as development of new or recurring symptoms prior to evidence of radiographic recurrence; those in this group had follow-up imaging confirming recurrence. Asymptomatic recurrence was defined as unequivocal evidence of recurrence on MRI. Results Median age for the symptomatic and asymptomatic groups was 58 and 57 years, respectively. Recursive partitioning analysis classes and other clinical factors were similar between both groups. The median time to recurrence was 9.5 months (range 3–49 months). Forty relapses (66.7 %) were symptomatic; 20 (33.3 %) were asymptomatic. Median overall survival (OS) for the symptomatic and asymptomatic cohorts was 17 and 23 months, respectively, a relative difference of 6 months (p = 0.08). Post-relapse survival was 3 months in patients who recurred symptomatically and 10 months for those who recurred by imaging (p = 0.06). Among the asymptomatic recurrence cohort, those who later went on to develop symptoms also had a median survival from symptom onset of 3 months. Conclusions In summary, OS is worse in GBM patients who present with symptoms at time of recurrence. This difference in survival is relatively large and should be validated in larger patient cohorts.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Glioblastoma multiforme (GBM)</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Symptomatic recurrence</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Asymptomatic recurrence</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Survival outcomes</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Altoos, Basel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Karam, Sana D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Waxweiler, Timothy V.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rusthoven, Chad G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gaspar, Laurie E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Honce, Justin M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Damek, Denise M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ney, Douglas E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ormond, D. Ryan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lillehei, Kevin O.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Changhu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kavanagh, Brian D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Arthur K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of radiation oncology</subfield><subfield code="d">Berlin : Springer, 2012</subfield><subfield code="g">5(2015), 1 vom: 12. Nov., Seite 33-39</subfield><subfield code="w">(DE-627)718611233</subfield><subfield code="w">(DE-600)2660511-9</subfield><subfield code="x">1948-7908</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:5</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">day:12</subfield><subfield code="g">month:11</subfield><subfield code="g">pages:33-39</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13566-015-0231-6</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">5</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="b">12</subfield><subfield code="c">11</subfield><subfield code="h">33-39</subfield></datafield></record></collection>
|
| score |
7.3989573 |